Today, Novo Nordisk estimates that just under 20 million people are treated with GLP-1 drugs.4 Given a well-stocked pipeline, a substantial global addressable population (the obese population alone is projected to exceed 1.2 billion by 20305), and in light of the very beneficial clinical profile of these drugs, it is plausible that over 100 million patients worldwide will be treated with GLP-1s in the near future
Occasional small treats can be part of a balanced approach
Include lean meats, fish, collagen peptides, eggs, and plant-based protein
The mean change in body weight from baseline to the last treatment visit was 2.2 kg greater in the LANTUS group than in the standard care group
Soltani N, Qiu H, Aleksic M, Glinka Y, Zhao F, Liu R, et al (2011) GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes